Powered by
-
ABBV Stock Chart
Historical ABBV Prices
AbbVie Stock Analysis
Rating: Buy
Total Grade: B
Analysis Breakdown
| ABBV Stock Grade: | B |
| Fundamental Grade: | C |
| Quantitative Grade: | B |
| ABBV Earnings | |
| Earnings Growth: | D |
| Earnings Momentum: | F |
| Earnings Surprises: | C |
| Analyst Earnings Revisions: | A |
| ABBV Financial Information | |
| Sales Growth: | B |
| Operating Margin Growth: | D |
| Cash Flow: | D |
| Return on Equity: | A |
AbbVie Stock: Weekly View
| This Week: | B |
|---|---|
| Last Week: | B |
| Two Weeks Ago: | B |
ABBV Stock predictions, Articles, and AbbVie News
- From InvestorPlace
- From the Web
-
5 Drug Stocks Poised to Surpass on Earnings This Quarter - April 17, 2018
The outlook for the upcoming first-quarter results looks bright. Compare Brokers.... Continue…
-
AbbVie Inc. Is a Clear Value Play in Biotech Stocks - April 17, 2018
AbbVie stock is not bouncing back after investors bailed on it following potentially negative clinical results. For value investors, ABBV trades at a discount to its peers but investors seem skittish of biotech's risks. When that changes, ABBV stock will be one of the first to recover. Continue…
-
4 Biotech Stocks With Leaky Pipelines - April 10, 2018
A strong pipeline can make or break biotech stocks, ensuring strong profits for years to come. These four biotech companies don't make the cut. Continue…
-
10 Safe Dividend Stocks for the Second Quarter - April 6, 2018
These 10 dividend stocks have been paying their shareholders for a long time and have a history of increases. Continue…
-
The 10 Best Stocks to Buy for April - April 3, 2018
Add these names to a list of stocks to buy sooner rather than later. Between seasonality and news, these tickers could buck the marketwide bearish trend. Continue…
-
Tread Very Carefully When Investing in AnaptysBio Inc - March 28, 2018
ANAB is up on positive clinical studies posted in the last few months. But the small sample size and risks ahead could hurt the stock in the near term. Continue…
-
AbbVie Inc Stock Dives on Lung Cancer Drug Results - March 22, 2018
AbbVie (ABBV) stock was falling hard today following results from a Phase 2 study of lung cancer drug Rovalpituzumab Tesirine. Continue…
-
Strong Buy for AbbVie (ABBV) This Week - March 16, 2018
At $114.93, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares. Continue…
-
Strong Buy for AbbVie (ABBV) This Week - March 15, 2018
At $118.94, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares. Continue…
-
Strong Buy for AbbVie (ABBV) This Week - March 8, 2018
The Strong Buy for AbbVie (ABBV) this week is based on the latest stock market rankings, and relative pricing of its shares. Continue…
